SANA
Overvalued by 96.4% based on the discounted cash flow analysis.
Market cap | $940.49 Million |
---|---|
Enterprise Value | $1.03 Billion |
Dividend Yield | $- (-) |
Earnings per Share | $-1.16 |
Beta | 1.91 |
Outstanding Shares | 238,409,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -3.74 |
---|---|
PEG | -4.33 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | -3.96 |
Enterprise Value to Net Income | -5 |
Total Debt to Enterprise | 0.15 |
Debt to Equity | 1.28 |
No data
No data
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana shares a vision of repairing and controlling genes, replacing missing or damaged cells, and making its therapies broadly avai...